Could TENS devices be a potential answer to the opioid crisis? If they are, it’ll be thanks to digital health.
Case in point is NeuroMetrix’s Quell device.
Transcutaneous electrical nerve stimulation (TENS) gizmos have been around for decades. But they’ve had a reputation for being unwieldy, with a bunch of wires and pads.
“TENS devices have been around for 40 years, and some of the reasons they’re not effective for chronic pain is that they are underpowered, not designed for 24/7 use, and they’re not dosing at the right levels for the individual. Treatment was left up to basically guess work,” said Frank McGillin, NeuroMetrix’s chief commercial officer. (Hear from McGillin in person at DeviceTalks Boston on Oct. 2.)
You may also like:
Registration is open for DeviceTalks Boston! Join us on June 5-6, 2019, as we explore the trends and technology that are shaping the future of the medical device industry.